Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00418782
Status:
TERMINATED
Last Update Posted:
2018-12-05
First Post:
2007-01-04
Brief Title:
A Study Of The Effect Of CE-224535 On Knee OA Osteoarthritis Pain
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A 2 Week Randomized Double Blind Placebo And Positive Controlled Parallel Group Multicenter Study Of CE-224535 In Subjects With Osteoarthritic Pain Of The Knee
Status:
TERMINATED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Results of interim analysis indicate lack of efficacy when compared to placebo
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CE-224535 is a new medication being developed as an analgesic and anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis OA The purpose of this study is to evaluate the analgesic and anti inflammatory efficacy and safety of CE 224535 versus placebo and naproxen treatment in patients with OA knee pain
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None